A. Gessain, R. Rua, E. Betsem, J. Turpin, and R. Mahieux, HTLV-3/4 and simian foamy retroviruses 313 in humans: Discovery, epidemiology, cross-species transmission and molecular virology

, Virology, vol.435, pp.187-99, 2013.

E. Betsem, R. Rua, P. Tortevoye, A. Froment, and A. Gessain, Frequent and recent human 316 acquisition of simian foamy viruses through apes' bites in Central Africa, PLoS Pathog, vol.7, p.1002306, 2011.

R. Rua and A. Gessain, Origin, evolution and innate immune control of simian foamy viruses 319 in humans, Curr Opin Virol, vol.10, pp.47-55, 2015.

C. Filippone, E. Betsem, P. Tortevoye, O. Cassar, S. Bassot et al., A 321 severe bite from a nonhuman primate is a major risk factor for HTLV-1 infection in hunters 322 from Central Africa, Clin Infect Dis, vol.60, pp.1667-76, 2015.

D. M. Pinto-santini, C. R. Stenbak, and M. L. , Foamy virus zoonotic infections, vol.324, p.55

F. Buseyne, E. Betsem, T. Montange, R. Njouom, C. Bilounga-ndongo et al., , p.326

, Clinical signs and blood test results among humans infected with zoonotic simian foamy 327 virus: a case-control study, J Inf Dis, vol.218, pp.144-151, 2018.

M. Schweizer, V. Falcone, J. Gange, R. Turek, and D. Neumann-haefelin, Simian foamy virus 329 isolated from an accidentally infected human individual, J Virol, vol.71, pp.4821-4824, 1997.

R. S. Boneva, W. M. Switzer, T. J. Spira, V. B. Bhullar, V. Shanmugam et al., , p.331

T. M. Folks and L. E. Chapman, Clinical and virological characterization of persistent human 332 infection with simian foamy viruses, AIDS Res Hum Retrov, vol.23, pp.1330-1337, 2007.

R. Rua, E. Betsem, S. Calattini, A. Saib, and A. Gessain, Genetic characterization of simian foamy 334 viruses infecting humans, J Virol, vol.86, pp.13350-13359, 2012.

S. Calattini, E. B. Betsem, A. Froment, P. Mauclere, P. Tortevoye et al., Simian foamy virus transmission from apes to humans, rural Cameroon, Emerg Inf, p.337
URL : https://hal.archives-ouvertes.fr/pasteur-00531282

. Dis, , vol.13, pp.1314-1320, 2007.

L. Jones-engel, C. C. May, G. A. Engel, K. A. Steinkraus, M. A. Schillaci et al.,

N. Chalise, M. M. Aggimarangsee, R. Feeroz, J. S. Grant, A. Allan et al.,

S. Kuller, R. Thongsawat, R. C. Chaiwarith, and M. L. Kyes, Diverse contexts of zoonotic 341 transmission of simian foamy viruses in Asia, vol.14, pp.1200-1208, 2008.

W. M. Switzer, S. H. Tang, S. Ahuka-mundeke, A. Shankar, D. L. Hanson et al.,

M. Wolfe, C. F. Lebreton, U. Djoko, A. Tamoufe, W. Esteban et al.,

E. O. Muyembe-tamfum, P. Wemakoy, N. A. Mulembakani, A. W. Hoff, and . Rimoin, Novel simian 345 foamy virus infections from multiple monkey species in women from the Democratic 346 Republic of Congo, Retrovirology, vol.9, p.13, 2012.

G. A. Engel, C. T. Small, K. Soliven, M. M. Feeroz, X. Wang et al., , p.348

K. L. Craig, D. L. Jackson, F. A. Iv, M. L. Linial, and L. Jones-engel, Zoonotic simian foamy 349 virus in Bangladesh reflects diverse patterns of transmission and co-infection. Emerg Microb 350 Infect, p.58, 2013.

R. Rua, E. Betsem, T. Montange, F. Buseyne, and A. Gessain, In vivo cellular tropism of gorilla 352 simian foamy virus in blood of infected humans, J Virol, vol.88, pp.13429-13464, 2014.

R. Rua, A. Lepelley, A. Gessain, and O. Schwartz, Innate sensing of foamy viruses by human 354 hematopoietic cells, J Virol, vol.86, pp.909-918, 2012.

C. Lambert, M. Couteaudier, J. Gouzil, L. Richard, T. Montange et al., , p.356

D. Lindemann, R. Njouom, A. Mouinga-ondeme, A. Gessain, and F. Buseyne, Potent neutralizing 357 antibodies in humans infected with zoonotic simian foamy viruses target conserved epitopes 358 located in the dimorphic domain of the surface envelope protein, PLoS Pathog, vol.14, p.359, 2018.

D. Kabat, S. L. Kozak, K. Wehrly, and B. Chesebro, Differences in CD4 dependence for infectivity 361 of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 362

, J Virol, vol.68, pp.2570-2577, 1994.

T. Wrin, T. P. Loh, J. C. Vennari, H. Schuitemaker, and J. H. Nunberg, Adaptation to persistent 364 growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 365 1 sensitive to neutralization by vaccine sera, J Virol, vol.69, pp.39-48, 1995.

R. F. Cook, S. L. Berger, K. E. Rushlow, J. M. Mcmanus, S. J. Cook et al., , p.367

C. J. Issel, Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious-368 anemia virus is linked to amino-acid substitutions in the surface unit envelope glycoprotein

, J Virol, vol.69, pp.1493-1499, 1995.

J. R. Mascola and B. F. Haynes, HIV-1 neutralizing antibodies: understanding nature's pathways

, Immunol Rev, vol.254, pp.225-244, 2013.

A. Mouinga-ondeme, M. Caron, D. Nkoghe, P. Telfer, P. Marx et al.,

M. Gessain and . Kazanji, Cross-species transmission of simian foamy virus to humans in rural 374

C. Gabon and . Africa, J Virol, vol.86, pp.1255-60, 2012.

P. D. Bieniasz, A. Rethwilm, R. Pitman, M. D. Daniel, I. Chrystie et al., A comparative 376 study of higher primate foamy viruses, including a new virus from a gorilla, Virology, vol.377, pp.217-228, 1995.

C. Lambert, R. Rua, A. Gessain, and F. Buseyne, A new sensitive indicator cell line reveals cross-379 transactivation of the viral LTR by gorilla and chimpanzee simian foamy viruses, Virology, vol.380, pp.219-226, 2016.

W. M. Schneider, M. Chevilotte, and C. M. Rice, Interferon-stimulated genes: a complex beb of 382 host defenses, Ann Rev Immunol, vol.32, pp.513-545, 2014.

F. Mcnab, K. Mayer-barber, A. Sher, A. Wack, and A. O'garra, Type I interferons in infectious 384 disease, Nat Rev Immunol, vol.15, pp.87-103, 2015.

D. Matthes, T. Wiktorowicz, J. Zahn, J. Bodem, N. Stanke et al., Basic 386 residues in the foamy virus Gag protein, J Virol, vol.85, p.27, 2011.

A. Bähr, A. Singer, A. Hain, A. A. Vasudevan, M. Schilling et al.,

R. Schweizer, S. König, D. Chanda, G. Häussinger, D. Kochs et al., Interferon 389 but not MxB inhibits foamy retroviruses. Virology, vol.488, p.28, 2016.

M. Lochelt, P. F.-romen, H. Bastone, N. Muckenfuss, Y. B. Kirchner et al., , p.391

A. Battenberg, E. Saib, K. Flory, C. Cichutek, and . Munk, The antiretroviral activity of APOBEC3 is 392 inhibited by the foamy virus accessory Bet protein, vol.102, pp.7982-7987, 2005.

R. A. Russell, H. L. Wiegand, M. D. Moore, A. Schafer, M. O. Mcclure et al., Foamy virus 394 Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral 395 defense factors, J Virol, vol.79, pp.8724-8731, 2005.

U. Berka, M. V. Hamann, and D. Lindemann, Early events in foamy virus-host interaction and 397 intracellular trafficking. Viruses, vol.5, pp.1055-74, 2013.

M. Kane, M. Trinity, . Zang, J. Suzannah, F. Rihn et al.,

S. J. Rice, P. D. Wilson, and . Bieniasz, Identification of interferon-stimulated genes with 400 antiretroviral activity, Cell Host Mic, vol.20, pp.392-405, 2016.

K. Plochmann, A. Horn, E. Gschmack, N. Armbruster, J. Krieg et al.,

D. Stirnnagel, A. Lindemann, C. Rethwilm, and . Scheller, Heparan sulfate is an attachment factor 403 for foamy virus entry, J Virol, vol.86, pp.10028-10035, 2012.

M. Picard-maureau, G. Jarmy, A. Berg, A. Rethwilm, and D. Lindemann, Foamy virus envelope 405 glycoprotein-mediated entry involves a pH-dependent fusion process, J Virol, vol.77, p.4722, 2003.

K. Stirnnagel, D. Schupp, A. Dupont, V. Kudryavtsev, J. Reh et al.,

. Lindemann, Differential pH-dependent cellular uptake pathways among foamy viruses 409 elucidated using dual-colored fluorescent particles, Retrovirology, vol.9, p.71, 2012.

K. Toyoshima and P. K. Vogt, Enhancement and inhibition of avian sarcoma viruses by 411 polycations and polyanions, Virology, vol.38, pp.414-440, 1969.

K. Clark, L. Plater, M. Peggie, and P. Cohen, Use of the pharmacological inhibitor BX795 to study 413 the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct 414 upstream kinase mediates Ser-172 phosphorylation and activation, J Biol Chem, vol.284, p.415, 2009.

C. E. Stewart, R. E. Randall, and C. S. Adamson, Inhibitors of the interferon response enhance virus 417 replication in vitro, PLoS One, vol.9, p.112014, 2014.

M. Cataldi, N. R. Shah, S. A. Felt, and V. Z. Grdzelishvili, Breaking resistance of pancreatic cancer 419 cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor 420 TPCA-1, Virology, vol.485, pp.340-54, 2015.

Z. Ma, S. E. Hopcraft, F. Yang, A. Petrucelli, H. Guo et al., NLRX1 422 negatively modulates type I IFN to facilitate KSHV reactivation from latency, PLoS Pathog, vol.423, p.40, 2017.

J. Decalf, M. Desdouits, V. Rodrigues, F. X. Gobert, M. Gentili et al.,

B. Mougel, P. Cunha-de-alencar, and . Benaroch, Sensing of HIV-1 entry triggers a type I interferon 426 response in human primary macrophages, J Virol, vol.427, p.41, 2017.

J. S. Rawlings, K. M. Rosler, and D. A. Harrison, The JAK/STAT signaling pathway, J Cell Sci, vol.428, pp.1281-1284, 2004.

G. Trobridge and D. W. Russell, Cell cycle requirements for transduction by foamy virus vectors 430 compared to those of oncovirus and lentivirus vectors, J Virol, vol.78, p.43, 2004.

D. Jaishankar, A. M. Yakoub, T. Yadavalli, A. Agelidis, N. Thakkar et al., , p.432

, An off-target effect of BX795 blocks herpes simplex virus type 1 infection of the eye, Sci Transl, p.433

. Med, , vol.434, p.44, 2018.

J. Nan, Y. Du, X. Chen, Q. Bai, Y. Wang et al., , p.435

, TPCA-1 is a direct dual inhibitor of STAT3 and NF-kappaB and regresses mutant EGFR-436 associated human non-small cell lung cancers, Mol Cancer Ther, vol.13, pp.617-646, 2014.

Y. D. Quan, H. T. Xu, Y. S. Han, T. Mesplede, and M. A. Wainberg, JAK-STAT Signaling Pathways 438 and Inhibitors Affect Reversion of Envelope-Mutated HIV-1, J Virol, p.91, 2017.

C. Gavegnano, M. Detorio, C. Montero, A. Bosque, V. Planelles et al., Ruxolitinib and 440 tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in 441 vitro, Antimicrob Agents Chemother, vol.58, pp.1977-1986, 2014.

G. M. Jakobsdottir, M. Iliopoulou, R. Nolan, L. Alvarez, A. A. Compton et al., On the 443 Whereabouts of HIV-1 Cellular Entry and Its Fusion Ports, Trends Mol Med, vol.23, pp.932-944, 2017.

A. Rhodes-feuillette, F. Saal, J. Lasneret, M. Santillana-hayat, and J. Peries, Studies on in vitro 445 interferon induction capacity and interferon sensitivity of simian foamy viruses, Arch Virol, vol.446, p.49, 1987.

A. Sabile, A. Rhodes-feuillette, F. Z. Jaoui, J. Tobaly-tapiero, M. L. Giron et al.,

. Canivet, vitro studies on interferon-inducing capacity and sensitivity to IFN of human 449 foamy virus. Res Virol, vol.147, pp.29-37, 1996.

P. C. Loh and K. S. Ang, Replication of human syncytium-forming virus in human cells: effect 451 of certain biological factors and selective chemicals, J Med Virol, vol.7, pp.67-73, 1981.

C. L. Hill, P. D. Bieniasz, and M. O. Mcclure, Properties of human foamy virus relevant to its 453 development as a vector for gene therapy, J Gen Virol, vol.80, pp.2003-2009, 1999.

V. Falcone, M. Schweizer, A. Toniolo, D. Neumann-haefelin, and A. Meyerhans, Gamma interferon 455 is a major suppressive factor produced by activated human peripheral blood lymphocytes 456 that is able to inhibit foamy virus-induced cytopathic effects, J Virol, vol.73, p.53, 1999.

O. Herchenroder, M. Lochelt, F. Buseyne, A. Gessain, M. A. Soares et al.,